In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions

Reference

• ANKIER, S. I. and GOA, K. L., 1988, Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs, 35, 42–62.
   PubMedGoogle Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• CHUNG, W. G. and CHA, Y. N., 1997, Oxidation of caffeine to theobromine and theophylline is catalyzed primarily by fiavin-containing monooxygenase in liver microsomes. Biochemical and Biophysical Research Communications, 235, 685–688.
   PubMed Web of Science ®Google Scholar
• COLLER, J. K., SomoGYI, A. A. and BOCHNER, F., 1999, Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica, 29, 973–986.
   PubMed Web of Science ®Google Scholar
• ECHIZEN, H., KAWASAKI, H., CHIBA, K., TANI, M. and ISHIZAKI, T., 1993, A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 264, 1425–1431.
   PubMed Web of Science ®Google Scholar
• FUJISAKI, H., HIROTSU, K., OGAWA, T., MIZUKI, K., MIZUTA, H. and ARIMA, N., 2001, Metabolism of quazepam and its metabolites in humans: identification of metabolic enzymes and evaluation of drug interaction in vitro. Xenobiotic Metabolism and Disposition, 16, 558–568. [in Japanese]
   Google Scholar
• GIANCARLO, G. M., VENKATAKRISHNAN, K., GRANDA, B. W., VON MOLTKE, L. L. and GREENBLATT, D. J., 2001, Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. European Journal of Clinical Pharmacology, 57, 31–36.
   PubMed Web of Science ®Google Scholar
• HALPERT, J. R., GUENGERICH, F. P., BEND, J. R. and CORREIA, M. A., 1994, Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology, 125, 163–175.
   PubMed Web of Science ®Google Scholar
• HARDIN, T. C., GRAYBILL, J. R., FETCHICK, R., WOESTENBORGHS, R., RINALDI, M. G. and KUHN, J. G., 1988, Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrobial Agents and Chemotherapy, 32, 1310–1313.
   PubMed Web of Science ®Google Scholar
• HEYKANTS, J., VAN PEER, A., VAN DE VELDE, V., VAN ROOY, P., MEULDERMANS, W., LAVRIJSEN, K., WOESTENBORGHS, R., VAN CUTSEM, J. and CAUWENBERGH, G., 1989, The clinical pharmacokinetics of itraconazole: an overview. Mycoses, 32, 67–87.
   PubMed Web of Science ®Google Scholar
• HILBERT, J. M., Tomo, L., MORITZEN, V., BARNETT, A., SYMCHOWICZ, S. and ZAMPAGLIONE, N., 1986, Relationships of brain and plasma levels of quazepam, fiurazepam, and their metabolites with pharmacological activity in mice. Life Sciences, 39,161–168.
   PubMedGoogle Scholar
• KATO, K., YASUI-FURUKORI, N., FUKASAWA, T., AOSHIMA, T., SUZUKI, A., KANNO, M. and OTANI, K., 2003, Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Therapeutic Drug Monitoring, 25, 473–477.
   Google Scholar
• KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERTON, R. M. and WATKINS, P. B., 1994, CYP3A gene expression in human gut epithelium. Pharmacogenetics, 4, 247–259.
   Google Scholar
• LAPPLE, F., VON RICHTER, 0., FROMM, M. F., RICHTER, T., THON, K. P., WISSER, H., GRIESE, E. U., EICHELBAUM, M. and KIVISTO, K. T., 2003, Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics, 13, 565–575.
   Google Scholar
• MANCY, A., DIJOL S., Poi., S., GUENGERICH, P. and MANSUY, D., 1996, Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry, 35, 16205–16212.
   Google Scholar
• NEGRONI, R. and ARECHAVALA, A. I., 1993, Itraconazole: pharmacokinetics and indications. Archives of Medical Research, 24, 387–393.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., ZHANG, Q. Y., DUNBAR, D. and KAMINSKY, L. S., 2001, Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metabolism and Disposition, 29, 347–352.
   PubMed Web of Science ®Google Scholar
• PAINE, M. F., KHALIGHI, M., FISHER, J. M., SHEN, D. D., KUNZE, K. L., MARSH, C. L., PERKINS, J. D. and THUMMEL, K. E., 1997, Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics, 283, 1552–1562.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ, R. J. and ACOSTA, D., JR, 1997, Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and fiavin-containing monooxygenases, Drug Metabolism and Disposition, 25, 772–777.
   Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L. L. and GREENBLATT, D. J., 2001, Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149–1179.
   PubMed Web of Science ®Google Scholar
• YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. and UNO, T., 1981, A pharmacolinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobiodynamics, 4, 879–885.
   PubMedGoogle Scholar
• YEUNG, C. K., LANG, D. H., THUMMEL, K. E. and RETTIE, A. E., 2000, Immunoquantitation of FM01 in human liver, kidney, and intestine. Drug Metabolism and Disposition, 28, 1107–1111.
   PubMed Web of Science ®Google Scholar
• ZAMPAGLIONE, N., HILBERT, J. M., NING, J., CHUNG, M., GURAL, R. and SYMCHOWICZ, S., 1985, Disposition and metabolic fate of 14C-quazepam in man. Drug Metabolism and Disposition, 13, 25–29.
   PubMed Web of Science ®Google Scholar
• ZHANG, Q. Y., DUNBAR, D., OSTROWSKA, A., ZEISLOFT, S., YANG, J. and KAMINSKY, L. S., 1999, Characterization of human small intestinal cytochromes P-450. Drug Metabolism and Disposition, 27, 804–809.
   PubMed Web of Science ®Google Scholar